When shawarma turns vegan
This tweaked version of the much-loved meal of Malayalis is on the menu at Grasshopper Gastronomics, a Thiruvananthapuram-based food tech startup, which takes a bold leap into the food arena with the world's first ready-to-eat vegan shawarma.
Now, what turns heads is not about how shawarma could be made without meat; it is about what makes up for its absence. The cheat ingredient here is the quintessential jackfruit, Kerala's own comfort food, which is cleverly done up in spices to replicate the texture and taste of traditional shawarma. Yet there is no oil, no preservatives, and no animal products.
Behind this culinary revolution is Kannan Parakunnel, who did not start out as a food entrepreneur. His journey began with a deeply personal crisis during the Covid pandemic when his mother was diagnosed with cancer. It was then that Kannan started rethinking everything, especially food. 'Eating healthy makes a person healthy,' he found himself believing. And from that thought, Grasshopper Gastronomics was born.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
an hour ago
- Mint
Eris Lifesciences betting on insulin expertise to boost its GLP-1 play
Eris Lifesciences is gearing up to take advantage of India's booming diabetes-obesity market. The Ahmedabad-based drugmaker stands to gain in the country's human insulin market as innovator Novo Nordisk vacates, and it is betting on its insulin platform to grab a significant share in the anti-obesity market. 'We have a very successful insulin business with close to 10% market share in the country now. And any company that sells insulin well has been able to do GLP-1 very well," CEO Krishnakumar Vaidyanathan toldMintin an interview. Danish drugmaker Novo Nordisk, which is the innovator of blockbuster anti-obesity drugs Ozempic and Wegovy, is also a market leader in insulin, with an over 50% market share in India. The market for weight loss drugs in India was over ₹600 crore in July 2025. Also Read: Piramal Pharma's loss narrows to Rs82 crore in June quarter Vaidyanathan explained that the insulin business involves building a patient service and care platform, which goes beyond just selling the product. '...there is active support from Eris' side at the patient's residence…given this insulin platform, we are very confident that we'll be able to make a success of GLP-1 as well, because it will ride on this platform," he said. Eris says they have a 'one of a kind" patient service model where they train patients to use insulin, while Novo has a service model as well and a wide network of physicians. GLP-1s or glucagon-like peptide-1 agonists are a class of drugs used to treat type-2 diabetes and obesity, which mimic the GLP-1 hormone produced in the gut to regulate blood sugar and appetite. Eris plans to rely on third parties for Active Pharmaceutical Ingredients (APIs), but will eventually bring regular semaglutide in-house. It will depend on third parties for the synthetic semaglutide API. Eris launched liraglutide, a GLP-1, in India last year and plans to be among the first wave of launches for generic semaglutide, which goes off patent in March 2026. It is not the only one. India's top drugmakers, including Dr Reddy's,Cipla, Sun Pharma,Zydus Lifesciences, and Natco, are gearing up to launch the generic semaglutide next year. The firm also has a pipeline of standalone insulin analogues and insulin analogues with GLP-1 combinations in preclinical and clinical trials. Insulin dominance Earlier this year, Novo Nordisk announced the rollback of pen-filled versions of its best-selling Human Mixtard insulin. While the vial versions will still be sold, this opens up a huge market for domestic players to fill in the country's ₹4,500 crore insulin market. Eris acquired the Insugen and Basalog brands fromBiocon Biologics last year as part of a larger deal to acquire its branded formulations business. It also sells Xsulin through a joint venture with MJ Biopharma. Also Read: Jashvik Capital acquires stake in pharma software firm for ₹400 crore Apart from innovators Novo Nordisk andSanofi, which dominate the Indian insulin market, Lupin, which acquired Eli Lilly's Huminsulin brand last year, is a key domestic player. 'So this whole democratisation of insulins and GLP-1s is something that is going to happen. The ball has been set rolling," said Vaidyanathan. Eris expects to see increased sales from recombinant human insulin (RHI) pen products in November and December as innovator inventory runs out. The company is also planning to in-source its insulin and GLP-1 production at a later stage. The company commenced production of insulin vials at its Bhopal facility in Q1FY26, and expects to start cartridge production by Q4FY26. 'Our strategy has always been that, once we deem that a product is big and strategically important, then we bring it in-house," said Vaidyanathan. Eris Lifesciences reported its Q1FY26 results on Tuesday, with its consolidated revenue up 7.4% year-on-year to ₹773 crore. Its Ebitda for the quarter stood at ₹277 crore, up 11% YoY with a 36% Ebitda margin. Net profit was up 41% to ₹125 crore. The drugmaker is focused on increasing profitability and paring down debt in FY26. Also Read: Sun Pharma net profit falls on US antitrust settlement, drug impairment costs 'All of this will be accompanied by a significant acceleration in the EPS (earnings per share) and the return ratios," said Vaidyanathan. Its EPS in Q1 was ₹9.2, and the company expects a 50% EPS growth in FY26. The company's net debt in Q1FY26 was ₹2,317 crore, and it aims to reduce debt to ₹1,800 crore by the end of the year.
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.
News18
3 hours ago
- News18
Delhi HC forms panel to determine autistic students school
Last Updated: New Delhi, Aug 5 (PTI) The Delhi High Court on Tuesday formed a committee of experts to evaluate whether a girl diagnosed with autism can be admitted in a private school in the capital or she needs a school for children with special needs. A bench of Chief Justice Devendra Kumar Upadhyaya and Justice Tushar Rao Gedela passed the order on an appeal filed by GD Goenka Public School against an order directing it to admit the child in Class 1, or in an age-appropriate class, as a fee-paying student. 'To allay apprehension in the mind of the appellant we propose constitution of a committee of experts, along with her mother and school counsellor, to evaluate the girl and give its opinion as to whether she can be admitted in G D Goenka or a school of children with special needs," the bench said. The bench also directed the doctor concerned to examine the child to conduct any study that was required to come to the conclusion. The court was hearing appeal against a July 1 order of a single judge of the high court, saying 'inclusive education" was about belongingness, recognising that every child had a place in the classroom not because they were the same, but because they were different, as the difference enriches the learning environment for all. The petition before the single judge bench claimed the child was born in May 2017, and in November 2019, a doctor suspected her to be suffering from autism and started her therapy, which was interrupted by Covid-19. The child was admitted to the school in academic session 2021-22 under the 'sibling clause" and her parents informed the institution about the speech delay in the admission forms. In December 2021, the child was diagnosed with mild autism and was recommended various therapies. When the offline classes resumed in April 2022 after the Covid-19, the parents submitted the diagnosis to the school and requested support in the form of a shadow teacher, or allowing 'special educator" to assist her in the classroom, the petition said. Due to constant pressure and lack of support from the school, education of the petitioner was stated to have been discontinued from January 2023. The court said the child should be permitted to attend school with the assistance of a parent-appointed shadow teacher, subject to the school's basic norms of decorum and safety. It further directed the Directorate of Education to monitor the reintegration of the child and ensure the school provides an inclusive and non-discriminatory environment. PTI UK UK AMK AMK view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
